Background Delirium is common in patients receiving palliative care. Management includes assessment, reversal of underlying causes, non-pharmacological interventions and family support. Given recent evidence, antipsychotics should be avoided in mild-moderate delirium. Methods A 20-question online anonymous survey was emailed to all Association for Palliative Medicine (APM) members. UK and Irish palliative medicine specialists in current clinical practice (n=859) were asked about delirium assessment, management and research priorities. Results Response rate was 39% (335/859). Of these, 70% (234/335) were consultants, 15% (51/335) were specialist trainee registrars in palliative medicine and 15% (50/335) were associate specialists. Overall, 85% (285/335) had over 5 years of specialist palliative medicine experience. They worked in a variety, and often multiple settings, across hospital, hospice and community. Delirium guidelines were inconsistently used, with 42% (115/276) using local guidelines and 38% (104/276) using no guidelines. Most, 184/314 (59%) never use a tool to screen for delirium at inpatient admission. Most would use non-pharmacological interventions to manage delirium, either alone (106/275; 39%) or more commonly with an antipsychotic (160/275; 58%). The majority, 248/273 (91%) would prescribe an antipsychotic to a delirious patient with distressing hallucinations, with 190/273 (70%) using typical antipsychotics and 43/273 (16%) using atypical antipsychotics first line. Most inpatient (153/270; 57%) and community teams (97/161; 60%) do not formally support family carers. Informal verbal support was offered by 24% (64/270) in the inpatient setting and 22% (35/161) in community settings. Research priorities were prevention, prediction of reversibility and management (non-pharmacological and pharmacological). Conclusion Most responding APM members do not formally screen for delirium at inpatient admission. Many use an antipsychotic along with non-pharmacological interventions to manage delirium, and nearly all prescribe an antipsychotic to treat distressing hallucinations. Further rigorously designed clinical trials are urgently needed in view of management variability, emerging evidence and perceived priorities for research.
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The aim of this systematic review was to find and assimilate the evidence assessing the association of benzodiazepines and Z-drugs with survival in patients with cancer, to assist in clinical decision-making regarding the use of these drugs in cancer patients. Methods Systematic review with narrative synthesis designed and conducted according to the recommendations set out in Preferred Reporting Items for Systematic Reviews and MetaAnalyses-Protocol (PRISMA-P) and PRISMA statements. The review protocol was registered on the PROSPERO prior to commencing the searches. The electronic databases MEDLINE, EMBASE, PsychINFO, Cochrane Library, AMED were searched and hand-searches were performed. Screening, extraction and quality assessment were performed in duplicate. Results A total of 2257 unique records were identified, 116 full-text articles assessed for eligibility, 18 met the inclusion criteria. These contained data on 4117 patients with cancer. All studies were low or very-low quality. Most studies were conducted in patients in the last days/weeks of life. No study found an association between benzodiazepines and survival in patients with cancer. Conclusions There is no evidence demonstrating an association between benzodiazepines and survival in patients with cancer. These results should be interpreted with caution as all studies were low/very low quality, most did not report or account for other medications and did not have survival as a primary outcome. No study assessed the effect of long-term benzodiazepines on survival. Therefore, definitive conclusions regarding survival impact of benzodiazepine in patients with cancer can be made. Further investigation using high-quality long-term randomised control trials with survival as a primary endpoint are needed. Background Oral fluid intake commonly reduces in advanced cancer patients as they approach the end of their lives. The relationship of oral fluid intake with thirst and survival has not been fully evaluated. Better understanding of how oral fluid intake affects physical health and clinical outcomes may enable health professionals to identify which patients require hydration-based support. Aim To explore the association of oral fluid intake with thirst and survival in advanced cancer patients. Method A secondary analysis of an observational study database of 90 patients with advanced cancer from a previous study by Nwosu et al 2016. Regression analysis evaluated the relationship between oral fluid intake and thirst, and examined the predictive properties of recorded variables. Kaplan-Meier analysis evaluated the relationship between survival and oral fluid intake. A Cox regression was used to adjust for potential confounding factors: performance status, metastatic disease and age.
